Latest & greatest articles for propranolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on propranolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on propranolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for propranolol

1. Propranolol’s effects on memory reconsolidation in patients with PTSD

Propranolol’s effects on memory reconsolidation in patients with PTSD "Propranolol’s effects on memory reconsolidation in patients with PTSD" by Samuel Taibi < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Posttraumatic stress disorder (PTSD) is a psychiatric disorder affecting millions of the US population. Symptoms and comorbidities of the disorder can (...) dramatically affect the lives the sufferers. First-line treatment has been either antidepressants, psychotherapy, or a combination of both. However, success rates are lacking. Recently, the beta blocker propranolol has been shown to have effects on disrupting memory reconsolidation in humans through inhibitory actions on protein synthesis and norepinephrine. This could potentially translate to disrupting the traumatic memories in PTSD and becoming an adequate treatment for the condition. Methods

2019 Pacific University EBM Capstone Project

2. Propranolol generally safe in treating childhood haemangioma birthmarks

Propranolol generally safe in treating childhood haemangioma birthmarks Propranolol generally safe in treating childhood haemangioma birthmarks Discover Portal Discover Portal Propranolol generally safe in treating childhood haemangioma birthmarks Published on 17 January 2017 doi: Treating ‘infantile haemangioma’ strawberry birthmarks with oral propranolol is known to be effective and in this review was associated with low levels of adverse events. The most common adverse events included (...) coldness in the hands and feet, diarrhoea, sleep disorders and upper respiratory infections. More serious problems such as low blood pressure, slow heart rate, over-reactivity of the airways and low blood sugar were also reported. Though rare, parents and prescribers need to be aware of these side effects. There is currently no UK guidance on treating haemangioma. The beta-blocker propranolol is usually used to treat heart conditions. Although commonly used, UK preparations of this drug

2019 NIHR Dissemination Centre

3. Comparison between combined propranolol with other therapies and propranolol monotherapy in the treatment of infantile hemangioma: a meta-analysis

Comparison between combined propranolol with other therapies and propranolol monotherapy in the treatment of infantile hemangioma: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

4. Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment (Full text)

Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment Angiosarcoma is the most common malignant cardiac tumor. Cardiac angiosarcoma is a highly lethal neoplasm that is largely resistant to conventional anti-cancer therapy. Mean survival of patients with cardiac angiosarcoma is only 4 months, and almost all patients will succumb to the disease within 1 year. The beta blocker propranolol is an emerging therapy against angiosarcoma (...) . When combined with conventional therapies, propranolol increases progression free and overall survival in patients with this tumor type. It is currently unknown if propranolol is capable of showing anti-cancer efficacy as a single agent therapy. We report a case of a 61 year old woman diagnosed with primary cardiac angiosarcoma and liver and lung metastases. This patient chose to decline conventional therapy, and instead was prescribed the beta blocker propranolol as a single agent treatment. After

2018 Oncoscience PubMed

5. Propranolol

Propranolol Top results for propranolol - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for propranolol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

6. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator

Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator Electrical storm (ES), characterized by unrelenting recurrences of ventricular arrhythmias, is observed in approximately 30% of patients with implantable cardioverter-defibrillators (ICDs) and is associated with high mortality rates.Sympathetic blockade with β-blockers, usually in combination with intravenous (IV) amiodarone, have proved highly effective in the suppression (...) of ES. In this study, we compared the efficacy of a nonselective β-blocker (propranolol) versus a β1-selective blocker (metoprolol) in the management of ES.Between 2011 and 2016, 60 ICD patients (45 men, mean age 65.0 ± 8.5 years) with ES developed within 24 h from admission were randomly assigned to therapy with either propranolol (160 mg/24 h, Group A) or metoprolol (200 mg/24 h, Group B), combined with IV amiodarone for 48 h.Patients under propranolol therapy in comparison with metoprolol-treated

2018 EvidenceUpdates

7. Propranolol generally safe in treating childhood haemangioma birthmarks

Propranolol generally safe in treating childhood haemangioma birthmarks Propranolol generally safe in treating childhood haemangioma birthmarks Discover Portal Discover Portal Propranolol generally safe in treating childhood haemangioma birthmarks Published on 17 January 2017 doi: Treating ‘infantile haemangioma’ strawberry birthmarks with oral propranolol is known to be effective and in this review was associated with low levels of adverse events. The most common adverse events included (...) coldness in the hands and feet, diarrhoea, sleep disorders and upper respiratory infections. More serious problems such as low blood pressure, slow heart rate, over-reactivity of the airways and low blood sugar were also reported. Though rare, parents and prescribers need to be aware of these side effects. There is currently no UK guidance on treating haemangioma. The beta-blocker propranolol is usually used to treat heart conditions. Although commonly used, UK preparations of this drug

2018 NIHR Dissemination Centre

8. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial

Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial Limited data are available on the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis (PVT). This study aimed to compare transjugular intrahepatic portosystemic shunt (TIPS) with covered stents versus endoscopic band ligation (EBL) plus propranolol for the prevention of variceal (...) rebleeding among patients with cirrhosis and PVT.Consecutive cirrhotic patients (94% Child-Pugh class A or B) with PVT who had variceal bleeding in the past 6 weeks were randomly assigned to TIPS group (n=24) or EBL plus propranolol group (EBL+drug, n=25), respectively. Primary endpoint was variceal rebleeding. Secondary endpoints included survival, overt hepatic encephalopathy (OHE), portal vein recanalisation and rethrombosis, other complications of portal hypertension and adverse events.During

2017 EvidenceUpdates

9. WITHDRAWN: Propranolol for migraine prophylaxis. (Full text)

WITHDRAWN: Propranolol for migraine prophylaxis. Propranolol is one of the most commonly prescribed drugs for migraine prophylaxis.We aimed to determine whether there is evidence that propranolol is more effective than placebo and as effective as other drugs for the interval (prophylactic) treatment of patients with migraine.Potentially eligible studies were identified by searching MEDLINE/PubMed (1966 to May 2003) and the Cochrane Central Register of Controlled Trials (Issue 2, 2003 (...) ), and by screening bibliographies of reviews and identified articles.We included randomised and quasi-randomised clinical trials of at least 4 weeks duration comparing clinical effects of propranolol with placebo or another drug in adult migraine sufferers.Two reviewers extracted information on patients, methods, interventions, outcomes measured, and results using a pre-tested form. Study quality was assessed using two checklists (Jadad scale and Delphi list). Due to the heterogeneity of outcome measures

2017 Cochrane PubMed

10. Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review (Full text)

Safety of Oral Propranolol for the Treatment of Infantile Hemangioma: A Systematic Review Given the widespread use of propranolol in infantile hemangioma (IH) it was considered essential to perform a systematic review of its safety. The objectives of this review were to evaluate the safety profile of oral propranolol in the treatment of IH.We searched Embase and Medline databases (2007-July 2014) and unpublished data from the manufacturer of Hemangiol/Hemangeol (marketed pediatric formulation (...) of oral propranolol; Pierre Fabre Dermatologie, Lavaur, France). Selected studies included ≥10 patients treated with oral propranolol for IH and that either reported ≥1 adverse event or effect (AE) or planned to capture AEs. Data capture was standardized and extracted study design, demographic characteristics, IH characteristics, intervention, and safety outcomes. AEs were assigned a system organ class and preferred term.A total of 83 of 398 identified literature records met the inclusion criteria

2016 EvidenceUpdates PubMed

11. A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis (PubMed)

A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis. More recent data suggest that carvedilol may be more effective for reducing the hepatic venous pressure gradient (HVPG) than propranolol. The primary aim of this study was to evaluate the hemodynamic response to carvedilol compared (...) with propranolol.A total of 110 patients with a baseline HVPG value >12 mm Hg were allocated randomly to receive either carvedilol or propranolol. The HVPG measurement was repeated after 6 weeks of daily medication. The primary end point was a ≥20% fall in HVPG compared with baseline or <12 mm Hg.The difference in the proportion of responders in the carvedilol (49.1%) vs. propranolol (30.9%) groups did not reach statistical significance in the intention-to-treat analysis (P=0.08). However, among patients

2016 EvidenceUpdates

12. Therapeutic Effect of Propranolol in Mexican Patients with Infantile Hemangioma (Full text)

Therapeutic Effect of Propranolol in Mexican Patients with Infantile Hemangioma Infantile hemangiomas are the most common childhood vascular tumors, occurring in 10 % of children aged less than 1 year. Propranolol, a β-adrenergic blocker mainly indicated for hypertension, has proven effective in treating these types of tumors.To evaluate the efficacy and adverse effects of propranolol in Mexican pediatric patients diagnosed with infantile hemangioma, treated with an extemporaneously compounded (...) solution of propranolol.An open prospective observational study at the Children's Hospital of the Californias in Tijuana, Mexico was performed on ambulatory pediatric patients between the ages of 3 and 12 months diagnosed with infantile hemangioma. Patients were treated with an oral solution of propranolol in doses ranging from 0.5 to 2.5 mg/kg/day. Children were monitored monthly by the physician in charge, at which time clinical and treatment data were collected.Over a period of 20 months, 31

2015 Drugs - real world outcomes PubMed

13. Propranolol (Hemangiol): the drug of first choice for severe infantile haemangiomas

Propranolol (Hemangiol): the drug of first choice for severe infantile haemangiomas Prescrire IN ENGLISH - Spotlight ''Propranolol (Hemangiol°): the drug of first choice for severe infantile haemangiomas '', 1 July 2015 {1} {1} {1} | | > > > Propranolol (Hemangiol°): the drug of first choice for severe infantile haemangiomas Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |    (...) |   |  Spotlight Propranolol (Hemangiol°): the drug of first choice for severe infantile haemangiomas FEATURED REVIEW Haemangiomas are benign vascular tumours that generally arise in the skin during the first days of life. When an infant requires medical treatment for haemangioma, oral propranolol is the drug of first choice. Full review (3 pages) available for download by subscribers. Abstract Haemangiomas are benign vascular tumours that generally arise in the skin during the first days

2015 Prescrire

14. A randomized, controlled trial of oral propranolol in infantile hemangioma. (PubMed)

A randomized, controlled trial of oral propranolol in infantile hemangioma. Oral propranolol has been used to treat complicated infantile hemangiomas, although data from randomized, controlled trials to inform its use are limited.We performed a multicenter, randomized, double-blind, adaptive, phase 2-3 trial assessing the efficacy and safety of a pediatric-specific oral propranolol solution in infants 1 to 5 months of age with proliferating infantile hemangioma requiring systemic therapy (...) . Infants were randomly assigned to receive placebo or one of four propranolol regimens (1 or 3 mg of propranolol base per kilogram of body weight per day for 3 or 6 months). A preplanned interim analysis was conducted to identify the regimen to study for the final efficacy analysis. The primary end point was success (complete or nearly complete resolution of the target hemangioma) or failure of trial treatment at week 24, as assessed by independent, centralized, blinded evaluations of standardized

2015 NEJM

15. [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)]

[Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] Propranolol – Nutzenbewertung gemass Section 35a SGB V [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] Propranolol – Nutzenbewertung gemass Section 35a SGB V [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Propranolol – Nutzenbewertung gemass Section 35a SGB V. [Propranolol - benefit assessment according to section 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 260. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Childs; Hemangioma; Infant

2015 Health Technology Assessment (HTA) Database.

16. Propranolol

Propranolol USE OF PROPRANOLOL IN PREGNANCY 0344 892 0909 USE OF PROPRANOLOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Propranolol is a non-selective beta-adrenoceptor blocking drug (...) propranolol exposure and women should be made aware of this lack of data. Studies of beta-blockers as a class have not, to date, provided conclusive evidence that use during pregnancy is associated with an increased risk of fetal structural malformations. Although some studies have suggested a possible increased risk of congenital heart defects, this has also been observed with other antihypertensive therapies and may therefore be non-drug-specific or linked to the underlying maternal condition. A meta

2014 UK Teratology Information Service

17. Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment)

Propranolol - Benefit assessment according to §35a Social Code Book V (dossier assessment) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Propranolol – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 November 2014). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A14-29 Propranolol – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A14-29 Version 1.0 Propranolol – Benefit assessment acc. to §35a Social Code Book V 26 November 2014 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Propranolol – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 August 2014 Internal Commission

2014 Institute for Quality and Efficiency in Healthcare (IQWiG)

18. Hemangiol - propranolol

Hemangiol - propranolol 20 February 2014 EMA/CHMP/8171/2014 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report HEMANGIOL International non-proprietary name: propranolol Procedure No: EMEA/H/C/002621/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 (...) 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu Product information Name of the medicinal product: HEMANGIOL Applicant: PIERRE FABRE DERMATOLOGIE Les Cauquillous 81506 LAVAUR FRANCE Active substance: PROPRANOLOL HYDROCHLORIDE International Nonproprietary Name/Common Name: PROPRANOLOL Pharmaco-therapeutic group (ATC Code): (C07) Therapeutic indication: HEMANGIOL is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: • Life- or function-threatening

2014 European Medicines Agency - EPARs

19. A randomized controlled trial of propranolol for infantile hemangiomas (PubMed)

A randomized controlled trial of propranolol for infantile hemangiomas Propranolol hydrochloride is a safe and effective medication for treating infantile hemangiomas (IHs), with decreases in IH volume, color, and elevation.Forty children between the ages of 9 weeks and 5 years with facial IHs or IHs in sites with the potential for disfigurement were randomly assigned to receive propranolol or placebo oral solution 2 mg/kg per day divided 3 times daily for 6 months. Baseline electrocardiogram (...) , echocardiogram, and laboratory evaluations were performed. Monitoring of heart rate, blood pressure, and blood glucose was performed at each visit. Children younger than 6 months were admitted to the hospital for monitoring after their first dose at weeks 1 and 2. Efficacy was assessed by performing blinded volume measurements at weeks 0, 4, 8, 12, 16, 20, and 24 and blinded investigator scoring of photographs at weeks 0, 12, and 24.IH growth stopped by week 4 in the propranolol group. Significant

2011 EvidenceUpdates

20. Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices

Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Randomized study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices Jutabha R, Jensen D M, Martin P, Savides T, Han S H, Gornbein J Record Status (...) . Of these, 197 were excluded from randomisation and 62 were randomised. Randomisation assigned 31 to prophylactic oesophageal variceal ligation and 31 to prophylactic propranolol. Study design The study was an RCT that was carried out in three centres (Los Angeles Medical Centre, San Diego Medical Centre and Veterans Administration Los Angeles HealthCare System). A separate randomisation schedule was provided for each centre in permuted blocks of 4. The follow-up period was up to 2 years. Treatment

2005 NHS Economic Evaluation Database.